Accent Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1050 Waltham St Ste 201, Lexington, Mass...Phone Number
(339) 970-7400Website
www.accenttx.comRevenue
$5.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
7
1
1
2
1
1
About Accent Therapeutics
Accent Therapeutics is focused on translating advanced scientific research into innovative therapies for cancer patients. The company applies its expertise in RNA-modifying protein biology to develop small molecule therapeutics targeting critical intracellular dependencies across various cancer types. With a strong pipeline of first-in-class and best-in-class programs, Accent aims to meet the significant unmet medical needs of large patient populations. Their collaborative team is dedicated to driving the development of life-changing therapeutics for those living with cancer.Explore more
Accent Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Accent Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Accent Therapeutics had a recent Job posting/layoffs
Accent Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Accent Therapeutics launches new products
Earning: See what the market has to say on Accent Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Accent Therapeutics
Check out if Accent Therapeutics is spiking on competitors!
Check if Accent Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Accent Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Accent Therapeutics
Find 2 more new buyers
Compare Similar Companies to Accent Therapeutics
Compare insights from companies similar to Accent Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Accent Therapeutics
$5.8M
11-50
Private
$178M
-
CK
Chenzhong KuangChief Scientific Officer and President
Company Profile Activity
Activity Insights
Accent Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Accent Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Accent Therapeutics.
Accent Therapeutics financials insights
Gather financial insights about Accent Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$40M
2020
Series B
$63M
2024
Series C
$75M
Accent Therapeutics Tech Stack
A closer look at the technologies used by Accent Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Events, Clinical Operations
Person-Based
Open Position
Open Position
Person-Based
Medical Research, Pharmaceuticals
Accent Therapeutics News & Media
Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics
Agreement to acquire Accent Therapeutics' asset adds to the Boehringer Ingelheim portfolio a highly innovative, potentially first-in-class oncology program targeting critical cancer vulnerabilities to improve cancer patient outcomes Preclinical small molecule offers a novel approach for...Accent Therapeutics Announces Trial in Progress Poster for First-in-Human Study of ATX-559 at 2025 ASCO Annual Meeting
ATX-559, a first-in-class oral DHX9 inhibitor, is being evaluated in a Phase 1/2 study with a focus on advanced or metastatic patients with BRCA-1 and/or BRCA-2-deficient breast cancer or MSI-H and/or dMMR solid tumors LEXINGTON, Mass., May 22, 2025 /PRNewswire/ -- Accent Therapeutics, a...Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Novel KIF18A Inhibitor ATX-295 and Receives FDA Fast Track Designation for Lead Assets ATX-295 and DHX9 Inhibitor ATX-559
First-in-human Phase 1/2 study initiated for ATX-295, a potential best-in-class oral inhibitor of KIF18A, focused on patients with advanced solid tumors including ovarian cancer FDA grants Fast Track designation to Accent's two lead clinical-stage programs – ATX-295 and ATX-559 – for the...Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition
Phase 1/2 study initiated for ATX-559, a first-in-class inhibitor of DHX9, focused on patients with BRCA1/2-deficient breast cancer and MSI-H and/or dMMR solid tumors Second program targeting KIF18A anticipated to enter the clinic in 1H 2025, treating patients with chromosomally instable...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Accent Therapeutics
Sign Up For FreeTo access detailed company insights
Accent Therapeutics is focused on translating advanced scientific research into innovative therapies for cancer patients. The company applies its expertise in RNA-modifying protein biology to develop small molecule therapeutics targeting critical intracellular dependencies across various cancer types. With a strong pipeline of first-in-class and be... Read More
